^
BIOMARKER:

NRAS mutation

i
Other names: NRAS1, HRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase
Entrez ID:
Related biomarkers:
NRAS mutation
CRC
panitumumab
Resistant: A1 - Approval
NRAS mutation
CRC
cetuximab
Resistant: A2 - Guideline
NRAS mutation
Melanoma
binimetinib
Sensitive: A2 - Guideline
NRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
NRAS mutation
Cutaneous Melanoma
binimetinib
Sensitive: A2 - Guideline
NRAS mutation
MDS
ruxolitinib
Sensitive: A2 - Guideline
NRAS mutation
AML
gilteritinib
Resistant: B - Late Trials
NRAS mutation
CRC
regorafenib
Sensitive: B - Late Trials
NRAS mutation
AML
azacitidine
Resistant: B - Late Trials
NRAS mutation
CRC
bevacizumab
Sensitive: C2 – Inclusion Criteria
NRAS mutation
NSCLC
LXH254
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Melanoma
FCN-159
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Melanoma
trametinib
Sensitive: C2 – Inclusion Criteria
NRAS mutation
NSCLC
trametinib
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Melanoma
BVD-523
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Melanoma
nivolumab
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Cutaneous Melanoma
AS703026
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Thyroid Gland Carcinoma
selumetinib
Sensitive: C2 – Inclusion Criteria
NRAS mutation
NSCLC
KO-947
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Melanoma
trametinib + palbociclib
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Pancreatic Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Thyroid Gland Carcinoma
trametinib
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Multiple Myeloma
selinexor
Sensitive: C3 – Early Trials
NRAS mutation
Childhood B Acute Lymphoblastic Leukemia
GS-9973
Resistant: C3 – Early Trials
NRAS mutation
AML
venetoclax
Resistant: C3 – Early Trials
NRAS mutation
AML
cytarabine
Resistant: C3 – Early Trials
NRAS mutation
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
NRAS mutation
Melanoma
trametinib + durvalumab
Sensitive: C3 – Early Trials
NRAS mutation
CRC
sorafenib
Sensitive: C3 – Early Trials
NRAS mutation
Melanoma
AS703026
Sensitive: C3 – Early Trials
NRAS mutation
CRC
EGFR inhibitor
Resistant: C3 – Early Trials
NRAS mutation
AML
venetoclax + midostaurin
Resistant: C3 – Early Trials
NRAS mutation
AML
venetoclax + gilteritinib
Resistant: C3 – Early Trials
NRAS mutation
AML
venetoclax + sorafenib
Resistant: C3 – Early Trials
NRAS mutation
Multiple Myeloma
venetoclax + cobimetinib
Sensitive: C3 – Early Trials
NRAS mutation
Cutaneous Melanoma
PD1 inhibitor
Resistant: C3 – Early Trials
NRAS mutation
Melanoma
ribociclib + binimetinib
Sensitive: C3 – Early Trials
NRAS mutation
Melanoma
pembrolizumab
Sensitive: C3 – Early Trials
NRAS mutation
Melanoma
AZD6738
Sensitive: C3 – Early Trials
NRAS mutation
Melanoma
HM95573
Resistant: C3 – Early Trials
NRAS mutation
Anaplastic Astrocytoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
NRAS mutation
AML
ivosidenib
Resistant: C3 – Early Trials
NRAS mutation
CMML
KB003
Sensitive: C3 – Early Trials
NRAS mutation
Melanoma
PD1 inhibitor + CTLA4 inhibitor
Sensitive: C3 – Early Trials
NRAS mutation
Multiple Myeloma
MEK inhibitor
Sensitive: C3 – Early Trials
NRAS mutation
NSCLC
lorlatinib
Resistant: C3 – Early Trials
NRAS mutation
Mucosal Melanoma
PD1 inhibitor
Resistant: C3 – Early Trials
NRAS mutation
Solid Tumor
selumetinib
Resistant: C3 – Early Trials
NRAS mutation
Mucosal Melanoma
cisplatin + temozolomide
Sensitive: C3 – Early Trials
NRAS mutation
Mucosal Melanoma
cisplatin + dacarbazine
Sensitive: C3 – Early Trials
NRAS mutation
Melanoma
cobimetinib + HM95573
Sensitive: C3 – Early Trials
NRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
binimetinib
Sensitive: C3 – Early Trials
NRAS mutation
AML
decitabine
Resistant: C3 – Early Trials
NRAS mutation
CRC
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
NRAS mutation
Melanoma
CH4987655
Sensitive: C4 – Case Studies
NRAS mutation
NSCLC
RAF709
Sensitive: D – Preclinical
NRAS mutation
AML
venetoclax + IACS-010759
Sensitive: D – Preclinical
NRAS mutation
Melanoma
LY3009120
Sensitive: D – Preclinical
NRAS mutation
Melanoma
CCT241161 + CCT196969
Sensitive: D – Preclinical
NRAS mutation
AML
mTOR inhibitor
Resistant: D – Preclinical
NRAS mutation
NSCLC
BI 6727 + LXH254
Sensitive: D – Preclinical
NRAS mutation
CRC
trametinib + dasatinib
Sensitive: D – Preclinical
NRAS mutation
AML
ixazomib
Sensitive: D – Preclinical
NRAS mutation
CRC
rigosertib
Sensitive: D – Preclinical
NRAS mutation
Melanoma
palbociclib + AZD1775 + PI-103
Sensitive: D – Preclinical
NRAS mutation
Melanoma
AZD1775
Sensitive: D – Preclinical
NRAS mutation
Melanoma
XL888
Sensitive: D – Preclinical
NRAS mutation
Endometrial Cancer
AZ 628
Sensitive: D – Preclinical
NRAS mutation
Endometrial Cancer
PD-0325901
Sensitive: D – Preclinical
NRAS mutation
NSCLC
selumetinib
Sensitive: D – Preclinical
NRAS mutation
CRC
TAK-733
Sensitive: D – Preclinical
NRAS mutation
CRC
cetuximab + LY3009120
Sensitive: D – Preclinical
NRAS mutation
NSCLC
AS703026
Sensitive: D – Preclinical
NRAS mutation
NSCLC
GDC 0879
Sensitive: D – Preclinical
NRAS mutation
Melanoma
SAB298
Sensitive: D – Preclinical
NRAS mutation
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical
NRAS mutation
Melanoma
cobimetinib + UNC2025
Sensitive: D – Preclinical
NRAS mutation
Melanoma
trametinib + encorafenib
Sensitive: D – Preclinical
NRAS mutation
Melanoma
SBI-726
Sensitive: D – Preclinical
NRAS mutation
Melanoma
KO-947
Sensitive: D – Preclinical
NRAS mutation
Melanoma
GDC 0879
Resistant: D – Preclinical
NRAS mutation
Melanoma
RAF709
Sensitive: D – Preclinical
NRAS mutation
Melanoma
palbociclib
Sensitive: D – Preclinical
NRAS mutation
Melanoma
BKM120
Sensitive: D – Preclinical
NRAS mutation
Melanoma
UNC2025
Sensitive: D – Preclinical
NRAS mutation
Pancreatic Cancer
KO-947
Sensitive: D – Preclinical
NRAS mutation
Melanoma
cetuximab + BGB659
Sensitive: D – Preclinical
NRAS mutation
Melanoma
CCT241161
Sensitive: D – Preclinical
NRAS mutation
Melanoma
trametinib + GSK2126458
Sensitive: D – Preclinical
NRAS mutation
Melanoma
MP470
Sensitive: D – Preclinical
NRAS mutation
CRC
GDC 0879
Resistant: D – Preclinical
NRAS mutation
Multiple Myeloma
midostaurin
Sensitive: D – Preclinical